|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F: The evolving scale and profile of
cancer worldwide: Much ado about everything. Cancer Epidemiol
Biomarkers Prev. 25:3–5. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bosetti C, Levi F, Rosato V, Bertuccio P,
Lucchini F, Negri E and La Vecchia C: Recent trends in colorectal
cancer mortality in Europe. Int J Cancer. 129:180–191. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, et al: Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce
future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Cutsem E, Peeters M, Siena S, Humblet
Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J,
Richardson G, et al: Open-label phase III trial of panitumumab plus
best supportive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorectal cancer.
J Clin Oncol. 25:1658–1664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mochizuki S and Okada Y: ADAMs in cancer
cell proliferation and progression. Cancer Sci. 98:621–628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Held-Feindt J, Paredes EB, Blömer U,
Seidenbecher C, Stark AM, Mehdorn HM and Mentlein R:
Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and
metalloproteinases with thrombospondin motifs 4 and 5) are
expressed in human glioblastomas. Int J Cancer. 118:55–61. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakada M, Miyamori H, Kita D, Takahashi T,
Yamashita J, Sato H, Miura R, Yamaguchi Y and Okada Y: Human
glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta
Neuropathol. 110:239–246. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Viapiano MS, Hockfield S and Matthews RT:
BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to
promote glioma invasion. J Neurooncol. 88:261–272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Demircan K, Gunduz E, Gunduz M, Beder LB,
Hirohata S, Nagatsuka H, Cengiz B, Cilek MZ, Yamanaka N, Shimizu K
and Ninomiya Y: Increased mRNA expression of ADAMTS
metalloproteinases in metastatic foci of head and neck cancer. Head
Neck. 31:793–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hurskainen TL, Hirohata S, Seldin MF and
Apte SS: ADAM-TS5, ADAM-TS6 and ADAM-TS7, novel members of a new
family of zinc metalloproteases. General features and genomic
distribution of the ADAM-TS family. J Biol Chem. 274:25555–25563.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Apte SS: A disintegrin-like and
metalloprotease (reprolysin-type) with thrombospondin type 1 motif
(ADAMTS) superfamily: Functions and mechanisms. J Biol Chem.
284:31493–31497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schaefer L and Schaefer RM: Proteoglycans:
From structural compounds to signaling molecules. Cell Tissue Res.
339:237–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kintakas C and McCulloch DR: Emerging
roles for ADAMTS5 during development and disease. Matrix Biol.
30:311–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cross NA, Chandrasekharan S, Jokonya N,
Fowles A, Hamdy FC, Buttle DJ and Eaton CL: The expression and
regulation of ADAMTS-1, −4, −5, −9 and −15 and TIMP-3 by TGFbeta1
in prostate cells: Relevance to the accumulation of versican.
Prostate. 63:269–275. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Porter S, Scott SD, Sassoon EM, Williams
MR, Jones JL, Girling AC, Ball RY and Edwards DR: Dysregulated
expression of adamalysin-thrombospondin genes in human breast
carcinoma. Clin Cancer Res. 10:2429–2440. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mizuno H, Kitada K, Nakai K and Sarai A:
PrognoScan: A new database for meta-analysis of the prognostic
value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Smith JJ, Deane NG, Wu F, Merchant NB,
Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, et al:
Experimentally derived metastasis gene expression profile predicts
recurrence and death in patients with colon cancer.
Gastroenterology. 138:958–968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim YH, Lee HC, Kim SY, Yeom YI, Ryu KJ,
Min BH, Kim DH, Son HJ, Rhee PL, Kim JJ, et al: Epigenomic analysis
of aberrantly methylated genes in colorectal cancer identifies
genes commonly affected by epigenetic alterations. Ann Surg Oncol.
18:2338–2347. 2011. View Article : Google Scholar : PubMed/NCBI
|
